Covalon Technologies Ltd. · TSXV:COV
Covalon Technologies — Shareholder Meeting (March 2026)
11 slides from Covalon Technologies's shareholder meeting presentation, Mar 25, 2026
Slide 1: Management Presentation
Management Presentation Brent Ashton Chief Executive Officer TSX-V: COV OTCQX: CVALF info@covalon.com
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements included in this presentation may be considered forward-looking statements. These forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “estimate”, “e
Slide 3: Covalon Addresses Some of Healthcare's Biggest Challenges
Covalon Addresses Some of Healthcare’s Biggest Challenges Vascular Access and Infusion Therapy • Over 1 billion IV lines placed per year • Both a lifeline and a significant risk • Serious complications such as infections and skin trauma can have catastrophic consequences to the patient, their family
Slide 4: Momentum Building for Covalon's Contamination Prevention Solution
Momentum Building for Covalon’s Contamination Prevention Solution • VALGuard® Line Guard + CovaClear® IV Cover dressings • Active shield of protection from contamination bugs • Significant momentum – clinicians, health systems, key opinion leaders • Similar past innovative technologies: • IV Skin Pr
Slide 5: Breakthrough Contamination Prevention Solution Gaining Significant Adoption and Attention
Breakthrough Contamination Prevention Solution Gaining Significant Adoption and Attention Recent Customer Wins Strong Engagement with Key Scientific Associations 19
Slide 6: Covalon Addresses Some of Healthcare's Biggest Challenges
Covalon Addresses Some of Healthcare’s Biggest Challenges Wound Care Chronic and Surgical Wounds • 300 million + wounds per year • Rapid healing without complications such as infections and skin trauma is critical • Chronic wounds create unique challenges • Covalon US growth of 35% (3 year CAGR) • C
Slide 7: Fiscal Year 2025 Financial Results
Fiscal Year 2025 Financial Results Change Change FY’24 FY’25 From FY’24 From FY’22 Revenue $31.2 $32.8 + 5.3% +81% Gross Profit $18.9 $17.5 - 7.7% +133% (Gross Margin) (60.7%) (53.2%) (-750 bps) (+1,190 bps) Operating Expenses $16.8 $15.7 - 6.5% -6% (As % to (53.8%) (47.9%) (-590 bps) (-4,380bps) Re
Slide 8: Market Valuation Lags Behind Industry Recognition
Market Valuation Lags Behind Industry Recognition • Growing engagement from organizations recognizing Covalon’s momentum • Increasing interest in partnerships, strategic alliances, and M&A opportunities • Clear validation from clinicians and health systems highlights the disconnect with current mark
Slide 9: Covalon Is On The Cusp Of A Meaningful Inflection Point
Covalon Is On The Cusp Of A Meaningful Inflection Point • Differentiated, high-impact solutions across our areas of focus • Rapid progress with contamination prevention solution – large upside potential • Financial turnaround has enabled growth acceleration phase • Acceleration in engagement from co
Slide 10: Q&A
Q&A 24
Slide 11: Investor Relations Contact Information
Investor Relations Contact Information Brent Ashton Katie Martinovich Chief Executive Chief Financial Officer Officer investors@covalon.com 25
Covalon Technologies — Shareholder Meeting (March 2026) on 6ix